Isaac Barchas Sells 83,094 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 83,094 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34. Following the completion of the sale, the director owned 125,410 shares of the company’s stock, valued at $3,023,635.10. The trade was a 39.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Price Performance

Shares of IMNM opened at $24.01 on Thursday. The stock has a 50-day moving average of $21.00 and a 200-day moving average of $21.86. The company has a market cap of $2.72 billion, a PE ratio of -10.09 and a beta of 2.07. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65.

Immunome (NASDAQ:IMNM) last issued its earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Immunome by 8,659.2% during the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares in the last quarter. Primecap Management Co. CA raised its position in Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after buying an additional 1,667,432 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Immunome in the 4th quarter valued at $30,710,000. Finally, Sofinnova Investments Inc. lifted its stake in Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after acquiring an additional 1,182,426 shares in the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on IMNM. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Wedbush reissued an “outperform” rating and issued a $31.00 price target on shares of Immunome in a research report on Friday, June 12th. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 price target for the company. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Immunome in a report on Wednesday, May 13th. Finally, Leerink Partners dropped their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.